Ocular Therapeutix IPO Info
Company Name: Ocular Therapeutix
Stock Symbol: OCUL
Exchange: NASDAQ
Status: Priced
IPO Date: 7/25/2014
IPO Price:
13.00 (
80.92%)
Underwriters
Morgan Stanley & Co., Cowen and Company and RBC Capital Markets
Amount of Offering: N/A
Number of Shares Offered: 5 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and Phase 2 clinical development for glaucoma, ocular hypertension and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, was approved by the U.S. Food and Drug Administration in January 2014 to seal corneal incisions following cataract surgery.
News Headlines
